[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100535333":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":124,"collaborators":7,"id":126,"slug":127,"hasResults":128,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":7,"eligibilityCriteria":131,"healthyVolunteers":128,"sex":132,"minAge":133,"maxAge":7,"enrollmentInfo":134,"targetDuration":137,"studyType":138,"phases":7,"briefSummary":139,"conditions":140,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Arbeitsgemeinschaft medikamentoese Tumortherapie","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Richard Greil, MD","Department of internal Medicine III, Paracelsus Medical University Salzburg, Austria","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Daniela Wolkersdorfer","CONTACT","+43 662 640 44 12","office@agmt.at",[20,36,48,60,72,80,88,100,112],{"facility":21,"status":22,"city":23,"state":7,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Landeskrankenhaus Feldkirch, Innere Med. II, Interne E","RECRUITING","Feldkirch","6807","Austria","AT",{"type":28,"coordinates":29},"Point",[30,31],9.59734,47.23645,{"lat":31,"lon":30},[34],{"name":35,"role":12,"phone":7,"phoneExt":7,"email":7},"Bernd Hartmann, MD",{"facility":37,"status":22,"city":38,"state":7,"zip":39,"country":25,"countryCode":26,"cosmosGeoPoint":40,"geoPoint":44,"contacts":45},"Univ.-Klinik für Innere Medizin V, Hämatologie\u002FOnkologie LKH-Innsbruck \u002F Universitätskliniken","Innsbruck","6020",{"type":28,"coordinates":41},[42,43],11.39454,47.26266,{"lat":43,"lon":42},[46],{"name":47,"role":12,"phone":7,"phoneExt":7,"email":7},"Dominik Wolf, MD",{"facility":49,"status":22,"city":50,"state":7,"zip":51,"country":25,"countryCode":26,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin \u002F Hämatologie \u002F Onkologie","Kufstein","6330",{"type":28,"coordinates":53},[54,55],12.16667,47.58333,{"lat":55,"lon":54},[58],{"name":59,"role":12,"phone":7,"phoneExt":7,"email":7},"August Zabernigg, MD",{"facility":61,"status":22,"city":62,"state":7,"zip":63,"country":25,"countryCode":26,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"KUK Linz: Klinik für Interne 3 - Schwerpunkt Hämatologie und Onkologie","Linz","4020",{"type":28,"coordinates":65},[66,67],14.28611,48.30639,{"lat":67,"lon":66},[70],{"name":71,"role":12,"phone":7,"phoneExt":7,"email":7},"Clemens Schmitt, MD",{"facility":73,"status":22,"city":62,"state":7,"zip":63,"country":25,"countryCode":26,"cosmosGeoPoint":74,"geoPoint":76,"contacts":77},"Ordensklinikum Linz GmbH - Barmherzige Schwestern; Interne I: Medizinische Onkologie und Hämatologie",{"type":28,"coordinates":75},[66,67],{"lat":67,"lon":66},[78],{"name":79,"role":12,"phone":7,"phoneExt":7,"email":7},"Manuel Orlinger, MD",{"facility":81,"status":22,"city":62,"state":7,"zip":63,"country":25,"countryCode":26,"cosmosGeoPoint":82,"geoPoint":84,"contacts":85},"Ordensklinikum Linz GmbH, Elisabethinen, I. Interne Abteilung Hämato-Onkologie",{"type":28,"coordinates":83},[66,67],{"lat":67,"lon":66},[86],{"name":87,"role":12,"phone":7,"phoneExt":7,"email":7},"Thomas Bauer, MD",{"facility":89,"status":22,"city":90,"state":7,"zip":91,"country":25,"countryCode":26,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"UK Salzburg, LKH: Universitätsklinik für Innere Medizin III","Salzburg","5020",{"type":28,"coordinates":93},[94,95],13.04399,47.79941,{"lat":95,"lon":94},[98],{"name":99,"role":12,"phone":7,"phoneExt":7,"email":7},"Alexander Egle, MD",{"facility":101,"status":22,"city":102,"state":7,"zip":103,"country":25,"countryCode":26,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Univ.-Klinikum St. Pölten, Innere Medizin 1","Sankt Pölten","3100",{"type":28,"coordinates":105},[106,107],15.63725,48.20762,{"lat":107,"lon":106},[110],{"name":111,"role":12,"phone":7,"phoneExt":7,"email":7},"Petra Pichler, MD",{"facility":113,"status":22,"city":114,"state":7,"zip":115,"country":25,"countryCode":26,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Klinikum Wels-Grieskirchen, Abteilung für Innere Medizin IV","Wels","4600",{"type":28,"coordinates":117},[118,119],14.03333,48.16667,{"lat":119,"lon":118},[122],{"name":123,"role":16,"phone":7,"phoneExt":7,"email":7},"Sonja Heibl, MD",{"type":125,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100535333","agmt-austrian-cll-chronic-lymphocytic-leukemia-registry-100535333",false,"NCT06250465","AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry","Inclusion Criteria:\n\n* The registry will include patients ≥ 18 years with CLL.\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria.","ALL","18 Years",{"count":135,"type":136},500,"ESTIMATED","5 Years","OBSERVATIONAL","For until very recently CLL has been considered an uncurable disease, with the only few exceptions of a part of patients capable of undergoing and successfully standing allogeneic stem cell transplant. However, the introduction of chemoimmunotherapy in particular the FCR (fludarabine, cyclophosphamide, rituximab) regimen has established a relevant population of IgVH mutated patients, who remain relapse-free for up to 10 years with a clear plateau at this level. However, for the largest proportion of all CLL patients the disease is still associated with a reduction in life expectancy as compared to a matched population.\n\nThe field has made further substantial progress by the introduction of BTK inhibitors and Bcl2 inhibitors, novel antibodies as well as by the understanding of the role of minimal residual disease (MRD), mutations and their clonal evolution over time as risk factors and factors governing the kind and duration of therapy.\n\nDue to the limited follow up of frontline therapy trials using novel drugs, it is not yet clear, what the long-term results with many of the new drugs will be. Particularly, long-term PFS, the potential for cure and the long-term safety issues remain relevant parameters requiring examination, as are infections, interactions with other drugs or quality of life issues.\n\nCLL has not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardized documentation of this disease.",[141],"Chronic Lymphocytic Leukemia","2025-04-09",{"date":144,"type":145},"2025-04-10","ACTUAL",{"date":147,"type":145},"2022-03-24",{"date":149,"type":136},"2027-12-31",{"name":5,"class":6},9]